Skip to Content

Osimertinib induction for patients with stage III metastatic EGFR NSCLC led to tumor shrinkage

Proffesor Nir Peled, oncologist, presents in this MEDtalk the efficacy of osimertinib as induction therapy before definitive radiotherapy (RT) in EGFRm stage III patients to induce tumor shrinkage and reduction of the radiation field

Nir Peled

Få adgang til artiklen

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top